According to reports from The Hindu BusinessLine, Alkem Laboratories Limited announced on Friday that Dr. Vikas Gupta has resigned from his position as Chief Executive Officer to pursue new professional opportunities. Dr. Gupta will remain in his role until June 30, 2026, to ensure a smooth handover of ongoing strategic initiatives and leadership responsibilities. The company has not yet named a successor to replace him.
As reported by The Hindu BusinessLine, markets reacted negatively to the leadership announcement. Alkem's shares on the NSE fell ₹154.50, or 2.80%, to ₹5,366 as of afternoon trade on Friday, against a previous close of ₹5,520.50. The stock touched an intraday low of ₹5,355, though it remains above its 52-week low of ₹4,716.20 recorded in July 2025. Sell orders significantly outpaced buy orders, with 61% of queued quantity on the sell side, indicating strong selling pressure following the announcement.
According to The Hindu BusinessLine, in his resignation letter, Dr. Gupta cited personal and long-term professional goals as reasons for his departure. He described the decision as difficult and credited his tenure with strengthening Alkem's market position and advancing its research and development pipeline. Dr. Gupta acknowledged the support of the promoter family and the board during his tenure.
As reported by The Hindu BusinessLine, Alkem Laboratories is a constituent of the Nifty Midcap 50 index and carries a total market capitalisation of approximately ₹64,111 crore. The stock trades at a price-to-earnings ratio of around 27. The company's shares have shown resilience despite the leadership transition, remaining above their 52-week low despite the recent decline.
